Singapore Approves Lumirix Cream for Nonsegmental Vitiligo in Patients Aged 12 and Older
Key Facts
Rxilient Medical, a subsidiary of China Medical System Holdings, received approval from Singapore’s Health Sciences Authority on November 3, 2026, to market ruxolitinib phosphate cream under the Lumirix brand. The approval authorizes its use to treat nonsegmental vitiligo with facial involvement in adults and adolescents aged 12 and older. The group announced the approval in a statement published via GlobeNewswire. The company said the drug is Singapore’s first prescription topical treatment to directly target the pathological mechanism of vitiligo. It presented the approval as a step toward addressing a treatment gap for patients, an argument attributed to the company’s statement.
The approval defines eligible patients by vitiligo type, affected area and age: it covers the nonsegmental form when the face is involved, starting with adolescents aged 12. The company statement says the target group also includes adults, but the information available here does not give the number of eligible patients or the size of Singapore’s market. The announcement also provides no figures on price or when sales will begin following approval. The company describes the drug as directly targeting the disease mechanism, a feature it highlights to explain its place among topical treatment options in the Singapore market. That wording remains the company’s description of the product, while the approval concerns the specific use announced by the authority.
Nonsegmental vitiligo is the most common form of the disease, according to the U.S. Food and Drug Administration, and causes loss of skin pigment in patches. This description provides background on the condition covered by the Singapore approval but does not change the stated scope of the indication for Lumirix cream. In Singapore, the approved use is limited to nonsegmental vitiligo with facial involvement in adults and adolescents aged 12 and older. The company statement gives no figures on the condition’s prevalence in the country or the number who might benefit from treatment. The announcement also provides no clinical results specific to Lumirix users in Singapore.
The ruxolitinib trials cited by the U.S. Food and Drug Administration provide a timeline for treatment: participants received the drug twice daily during an initial period of 24 weeks, after which all continued treatment for an additional 28 weeks. This information relates to trials cited by the agency in the context of its approval of Opzelura and does not represent data from a local trial of Lumirix cream. The agency’s statement says the most common side effects associated with Opzelura included acne and itching at the application site, colds, headache, urinary tract infection, redness at the application site and fever. The agency also noted reports of serious infections and other serious risks with JAK inhibitors used to treat inflammatory conditions. These details help place ruxolitinib’s mechanism and use in a broader context, while the cited trial data remain tied to the U.S. product and context.
As background to Lumirix’s regional expansion, a China Medical System interim announcement on the first six months of 2026 showed that Taiwan approved the drug in July of that year and listed Hong Kong and Macau among the regions where it had received approvals. That announcement dates from before Singapore’s approval and does not by itself establish that sales began in those markets. Singapore now joins the group’s approval path for the product in the region, according to its announcement dated November 3, 2026. China approved Lumirix on September 3, 2026, to treat atopic dermatitis, according to an earlier EL7 report. These approvals reflect different regulatory uses for the product across multiple markets; the Singapore announcement gives no timetable for next steps or sales to begin.